STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that ...

Alzheimer’s Disease (AD), that steal away mental faculties and debilitates day to day life of patients, may soon have a game-changing path for not just its treatment, but also ...

Sleep and brain experts respond to new findings on the association between REM sleep and Alzheimer's disease, recommending ...

Unlike most cells in the human body, neurons—the functional cells of our nervous system—cannot typically replace themselves ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia ...

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule ...

A tiny flower-shaped particle could help to pave the way for a new treatment approach to Alzheimer's and Parkinson's that targets the root causes.

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.